Table 4.

Baseline features and symptoms of patients with and without liver cirrhosis

Variable		No liver cirrhosis61 (48.8%)	Liver cirrhosis 64 (51.2%)	P value
Gender	Male	42 (68.9%)	44 (68.8%)	0.57
	Female	19 (31.1%)	20 (31.3%)
Age (yr)	20 to 30	0 (0.0%)	1 (1.6%)	0.004
	30 to 40	3 (4.9%)	3 (4.8%)
	40 to 50	0 (0.0%)	10 (15.9%)
	50 to 60	19 (31.1%)	12 (19.0%)
	60 to 70	14 (23.0%)	21 (33.3%)
	70 to 80	21 (34.4%)	14 (22.2%)
	80 to 90	4 (6.6%)	2 (3.2%)
Cigarette smoking		2 (3.2%)	8 (11.5%)	0.06
Diabetes mellitus		24 (39.3%)	28 (43.8%)	0.71
Hypertension		23 (37.7%)	29 (45.3%)	0.46
COPD		0 (0.0%)	1 (1.6%)	1
Coronary artery disease		5 (8.2%)	7(10.9%)	0.76
Chronic renal insufficiency		4 (6.6%)	4 (6.3%)	1
Heart failure		0	2 (3.1%)	0.49
Hepatocellular carcinoma		3 (4.9%)	12 (18.8%)	0.026
Esophageal varices		0 (0.0%)	9 (14.1%)	0.003
Asymptomatic		1 (1.6%)	4 (6.3%)	0.36
Fever		35 (57.4%)	43 (67.2%)	0.27
Cough		18 (29.5%	37 (57.8%)	0.002
Dyspnea		44 (72.1%)	36 (56.3%)	0.09
Sore throat		2 (3.3%)	13 (20.3%)	0.005
Hemoptysis		0 (0.0%)	1 (1.6%)	1
Fatigue		5 (8.2%)	21 (32.8%)	0.001
Anorexia		1 (1.6%)	3 (4.7%)	0.62
Diarrhea		0 (0.0%)	5 (7.8%)	0.05
Nausea		1 (1.6%)	2 (3.1%)	1
Vomiting		1 (1.6%)	2 (3.1%)	1
Abdominal pain		1 (1.6%)	0 (0.0%)	0.48
Arthralgia		1 (1.6%)	4 (6.3%)	0.36
Myalgia		1 (1.6%)	11 (17.2%)	0.004
Loss of taste		0 (0.0%)	2 (3.1%)	0.49
Loss of smell		0 (0.0%)	1 (1.6%)	1
Disturbed consciousness		3 (4.9%)	19 (29.7%)	0.001
Hepatic encephalopathy		0 (0.0%)	15 (23.4%)	0.033
Direct-acting antiviral therapy with sustained virological response before COVID-19 infection		7 (11.5%)	10 (15.6%)	0.61

COPD: Chronic obstructive pulmonary disease; COVID-19: Coronavirus disease 2019.